Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took the third dose of Vivotif a day later and the fourth dose took 30 hours after the third dose.; Case reference number US-BN-2024-002800 is a spontaneous case initially received from a nurse via Med Communications (reference number: USBAV24-3068) on 20-Nov-2024 and concerns an adult female patient born in 1978. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at unknown dose, orally, for unknown indication. On an unspecified date, unknown amount of time after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unspecified date, unknown amount of time after the first dose of Vivotif, reported as a day later, the patient took the third dose of Vivotif (batch number: unknown), at unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). On an unspecified date, unknown amount of time after first dose of Vivotif, as reported, 30 hours after the third dose of Vivotif the patient took the fourth dose of Vivotif (batch number: unknown), at unknown doe, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241120-7903b0 to US-BAVARIAN NORDIC A/S-US-BN-2024-002800, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: An adult female patient born in 1978 took the third dose of Vivotif for unknown indication, reported as a day later, which is considered as inappropriate schedule of vaccine administered. On an unspecified date, as reported, 30 hours after the third dose of Vivotif, the patient took the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An adult female patient born in 1978 took the third dose of Vivotif for unknown indication, reported as a day later, which is considered as inappropriate schedule of vaccine administered. On an unspecified date, as reported, 30 hours after the third dose of Vivotif, the patient took the fourth dose of Vivotif, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious. USBAV24-3068:
Comments: None.